Annex 1: Measuring progress towards targets
Annex 2: Modelling the impact of the 90-(90)-90 strategy
Annex 3: Investment packages by country setting
Annex 4: Country strategies
Annex 5: Strategic frameworks for research and development for new tools
Annex 6 : Estimating the cost of the 90-(90)-...90 strategy
Accessed November 2017
more
This technical package represents a select group of strategies based on the best available evidence to help communities and states sharpen their focus on prevention activities with the greatest potential to prevent suicide
PQDx 0141-051-00 WHO
PQDx Public Report
April/2017, version 5.0
Global HIV Strategic Information Working Group
For Populations At Risk For HIV
Practical Guidance for collaborative interventions
Treating children infected with intestinal worms is one of the simplest and most cost–effective ways to improve their health.
The recommendations are intended for a wide audience, including policy-makers and their expert advisers as well as technical and programme staff at government institution...s and organizations involved in the design, implementation and expansion of programmes to control soil-transmitted helminth infections.
more
Supplement article
The Journal of Infectious Diseases® 2017;216(S7):S675–8
DOI: 10.1093/infdis/jix368
Finding the Missing Tuberculosis Patients • JID 2017:216 (Suppl 7) • S675
Downloaded from https://academic.oup.com/jid/article-abstract/216/suppl_7/S675/4595547
by guest on 13 Nove...mber 2017
more
Lessons from the STEP-TB Project.
Accessed November 2017.
A compendium of TB REACH case studies, lessons learned and a monitoring and evaluation framework.
Accessed November 2017.
A review of available evidence (2016).
28-29 June 2016; Geneva, Switzerland
The END TB strategy.
Report: A survey conducted among the 27 high MDR-TB burden countries.
March – July 2015
Stop TB Partnership in collaboration with Medecins Sans Frontieres (MSF).
Accessed November 2017.
PLoS ONE 12(7): e0180996. https://doi.org/10.1371/journal.pone.0180996
Lancet Planet Health 2017 Published Online November 6, 2017 http://dx.doi.org/10.1016/S2542-5196(17)30141-9
Guidelines for treatment of drug-susceptible tuberculosisand patient care
2017 Update
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more